EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The event will take place on Thursday, August 15th, 2024.
Dr. Jay S. Duker, President and CEO of EyePoint, will present a Company Overview available on-demand from 7:00 a.m. ET. Additionally, he will participate in a panel discussion on 'The Evolving Therapeutic Landscape of AMD' at 9:00 a.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website. The replay will remain available for 90 days after the event.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda focalizzata nello sviluppo di terapie innovative per gravi malattie retiniche, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright. L'evento si svolgerà giovedì 15 agosto 2024.
Il Dott. Jay S. Duker, Presidente e CEO di EyePoint, presenterà una disponibile on-demand dalle 7:00 a.m. ET. Inoltre, parteciperà a una tavola rotonda su 'Il paesaggio terapeutico in evoluzione della AMD' alle 9:00 a.m. ET.
Gli investitori possono accedere a webcast dal vivo e a registrazioni archiviate di entrambe le presentazioni attraverso la sezione Investitori del sito web di EyePoint. La registrazione rimarrà disponibile per 90 giorni dopo l'evento.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una empresa centrada en desarrollar terapias innovadoras para enfermedades retinianas graves, ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright. El evento se llevará a cabo el jueves 15 de agosto de 2024.
El Dr. Jay S. Duker, Presidente y CEO de EyePoint, presentará una visión general de la empresa disponible a demanda a partir de las 7:00 a.m. ET. Además, participará en un panel de discusión sobre 'El paisaje terapéutico en evolución de la AMD' a las 9:00 a.m. ET.
Los inversores pueden acceder a las transmisiones web en vivo y a repeticiones archivadas de ambas presentaciones a través de la sección de Inversores del sitioweb de EyePoint. La repetición estará disponible durante 90 días después del evento.
아이포인트 제약 (NASDAQ: EYPT)는 심각한 망막 질환을 위한 혁신 치료제 개발에 중점을 둔 회사로, H.C. 웨인라이트 제4회 연례 안과 가상 회의에 참여한다고 발표했습니다. 이 행사는 2024년 8월 15일 목요일에 열릴 예정입니다.
아이포인트의 회장 겸 CEO인 제이 S. 듀커 박사는 회사 개요를 발표하며, 이는 동시 송출로 오전 7시(동부 표준시)부터 이용 가능합니다. 또한 그는 오전 9시(동부 표준시)부터 'AMD의 발전하는 치료 환경'에 관한 패널 토론에 참여할 것입니다.
투자자들은 아이포인트 웹사이트의 투자자 섹션을 통해 두 프레젠테이션의 실시간 웹캐스트 및 기록된 재방송에 접근할 수 있습니다. 재방송은 행사가 끝난 후 90일 동안 이용 가능합니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT), une entreprise axée sur le développement de thérapies innovantes pour des maladies rétiniennes graves, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle en Ophtalmologie H.C. Wainwright. L'événement se déroulera jeudi 15 août 2024.
Le Dr Jay S. Duker, Président et CEO d'EyePoint, présentera un aperçu de l'entreprise disponible à la demande à partir de 7h00 ET. De plus, il participera à une table ronde sur 'Le paysage thérapeutique en évolution de la DMLA' à 9h00 ET.
Les investisseurs peuvent accéder aux webdiffusions en direct et aux rediffusions archivées des deux présentations via la section Investisseurs du site web d'EyePoint. La rediffusion restera disponible pendant 90 jours après l'événement.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Unternehmen, das sich auf die Entwicklung innovativer Therapeutika für schwerwiegende Netzhauterkrankungen konzentriert, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet am Donnerstag, den 15. August 2024 statt.
Dr. Jay S. Duker, Präsident und CEO von EyePoint, wird eine Unternehmensübersicht präsentieren, die ab 7:00 Uhr ET auf Abruf verfügbar ist. Darüber hinaus wird er an einer Paneldiskussion über 'Die sich entwickelnde therapeutische Landschaft der AMD' um 9:00 Uhr ET teilnehmen.
Investoren können über den Investor-Bereich der EyePoint-Website auf Live-Webcasts und archivierte Wiederholungen beider Präsentationen zugreifen. Die Wiederholung bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference:
- Company Overview
Date: Thursday, August 15th, 2024
Time: Available on-demand at 7:00 a.m. ET
- The Evolving Therapeutic Landscape of AMD Panel Discussion
Date: Thursday, August 15th, 2024
Time: 9:00 a.m. ET
A live webcast and subsequent archived replay of the panel and the on-demand company overview may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and diabetic macular edema (DME). EyePoint expects to randomize patients for inclusion in pivotal Phase 3 clinical trials in wet AMD in 2024.
Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When is EyePoint Pharmaceuticals (EYPT) presenting at the H.C. Wainwright Ophthalmology Conference?
What topics will EyePoint Pharmaceuticals (EYPT) discuss at the conference?
How can investors access EyePoint Pharmaceuticals' (EYPT) presentations from the conference?
Who will represent EyePoint Pharmaceuticals (EYPT) at the H.C. Wainwright Ophthalmology Conference?
